On October 2, the Centers for Medicare & Medicaid Services (CMS) released final guidance outlining how the agency will implement the Inflation Reduction Act’s (IRA) Medicare Drug Price Negotiation Program (the “Program”) for initial price applicability year (IPAY) 2027, the second year for which CMS-negotiated prices will apply. The final guidance also provides more clarity on how manufacturers of drugs selected for both IPAY 2026 and 2027 will make their drugs available to Medicare…
By: Manatt, Phelps & Phillips, LLP
By: Manatt, Phelps & Phillips, LLP
